Perdoceo Education (PRDO) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Total student enrollments increased 11.0% year-over-year, with CTU up 13.6% and AIUS up 4.0%, reaching multi-year highs in retention rates.
Q3 2024 operating results exceeded expectations, with strong student retention and engagement at both CTU and AIUS.
Operating income for Q3 2024 increased 4.0% to $44.8 million, driven by lower expenses offsetting revenue declines.
Revenue for Q3 2024 declined 5.6% to $169.8 million, reflecting operational changes and academic calendar impacts.
The pending acquisition of the University of St. Augustine for $142–$144 million in cash is expected to close in December, expanding health science offerings and being accretive to adjusted operating income in 2025.
Financial highlights
Net income for Q3 2024 was $38.3 million ($0.57 per diluted share), down from $41.3 million ($0.62 per share) in the prior year; adjusted EPS was $0.59 versus $0.64.
Q3 revenue was $169.8 million, down 5.6% year-over-year; year-to-date revenue was $504.8 million, down 10.2%.
Adjusted operating income rose to $48.6 million from $47.2 million, and Q3 operating income was $44.8 million (+4.0%).
Net cash flows from operations year-to-date were $144.0 million, up from $98.8 million in the prior year.
Cash, equivalents, and short-term investments at quarter-end totaled $722.6 million, an increase of $118.4 million since year-end.
Outlook and guidance
Full-year 2024 adjusted operating income is now expected between $188 million and $191 million, up from prior guidance.
Adjusted EPS for 2024 is projected at $2.25–$2.28, with Q4 adjusted EPS outlook $0.46–$0.49.
Q4 2024 adjusted operating income expected at $39–$42 million.
Effective tax rate for full year 2024 expected between 26% and 27%.
Guidance assumes stable student interest, no major regulatory changes, and a 26.5% effective tax rate.
Latest events from Perdoceo Education
- 2025 saw double-digit growth in revenue, income, and enrollments, with strong 2026 guidance issued.PRDO
Q4 202519 Feb 2026 - Revenue and net income fell, but strong CTU growth and a dividend hike signal confidence.PRDO
Q2 20242 Feb 2026 - Q1 2025 revenue up 26.6% to $213M, driven by USAHS acquisition and enrollment growth.PRDO
Q1 202526 Dec 2025 - Q4 2024 saw record revenue and operating income, with 2025 set for further growth post-acquisition.PRDO
Q4 202423 Dec 2025 - Annual meeting to vote on directors, pay, and auditor amid growth, governance, and ESG focus.PRDO
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor ratification.PRDO
Proxy Filing2 Dec 2025 - Q2 2025 revenue and enrollments surged, with higher dividends and a new $75M buyback program.PRDO
Q2 202516 Nov 2025 - Q3 2025 delivered strong revenue, income, and enrollment growth, with robust shareholder returns.PRDO
Q3 20255 Nov 2025